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ABSTRACT
The increasing trend of carbapenem resistance in Acinetobacter baumannii worldwide is a concern since it
limits drastically the range of therapeutic alternatives. Metallo-b-lactamases (VIM, IMP, SIM) have been
reported worldwide, especially in Asia and western Europe, and confer resistance to all b-lactams except
aztreonam. The most widespread b-lactamases with carbapenemase activity in A. baumannii are
carbapenem-hydrolysing class D b-lactamases (CHDLs) that are mostly specific for this species. These
enzymes belong to three unrelated groups of clavulanic acid-resistant b-lactamases, represented by
OXA-23, OXA-24 and OXA-58, that can be either plasmid- or chromosomally-encoded. A. baumannii also
possesses an intrinsic carbapenem-hydrolysing oxacillinase, the expression of which may vary, that may
play a role in carbapenem resistance. In addition to b-lactamases, carbapenem resistance in A. baumannii
may also result from porin or penicillin-binding protein modifications. Several porins, including the 33-
kDa CarO protein, that constitute a pore channel for influx of carbapenems, might be involved in
carbapenem resistance.
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INTRODUCTION
Acinetobacter baumannii is an opportunistic patho-
gen that is frequently involved in outbreaks of
infection, occurring mostly in intensive care units
[1]. A. baumannii is mostly a cause of septicaemia,
pneumonia and urinary tract infection following
hospitalisation of patients with more severe ill-
ness. Multidrug-resistant isolates of A. baumannii
have been reported increasingly during the last
decade, probably as a consequence of extensive
use of antimicrobial agents in western countries
[2]. Carbapenem resistance in this species is now
observed increasingly worldwide, and constitutes
a sentinel event for emerging antimicrobial resist-
ance [3]. It is considered that resistance against
carbapenems is, in itself, sufficient to define an
isolate of A. baumannii as highly resistant [4].
Several studies focusing on the genetic and
biochemical basis of carbapenem resistance in
A. baumannii have been reported recently, mostly
related to b-lactamase production.
Two intrinsic types of b-lactamases can be
identified in most, if not all, A. baumannii isolates.
An AmpC-type cephalosporinase, expressed at a
basal level, does not reduce the efficacy of
expanded-spectrum cephalosporins [5]; however,
introduction of the insertion sequence ISAba1
upstream of the blaAmpC gene enhances b-lacta-
mase expression considerably by providing
promoter sequences, resulting in resistance to
ceftazidime, but not to carbapenems [6–8]. A. bau-
mannii also produces a second intrinsic b-lacta-
mase, which is an oxacillinase represented by the
OXA-51 ⁄ 69 variants [9,10]. The genes encoding
the blaOXA-51-like b-lactamases are chromosomally
located in all of the A. baumannii isolates studied
to date. OXA-51 ⁄ 69 enzymes share very weak
identities with other known oxacillinases. To date,
11 variants of OXA-51 have been identified in
isolates from diverse geographical origins [11,12].
Among these variants, the OXA-51 and OXA-69
b-lactamases have been studied in detail to
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elucidate their carbapenemase activities [9,10].
However, it seems that the level of expression of
the corresponding genes is quite low in most
cases and, even after it has been cloned into high-
copy-number plasmids in Escherichia coli and
A. baumannii, OXA-69 has only a marginal impact
on susceptibility to all b-lactams, including carb-
apenems [9]. Thus, in summary, A. baumannii, like
Pseudomonas aeruginosa, produces a naturally
occurring AmpC b-lactamase, together with a
naturally occurring oxacillinase with carbapene-
mase properties [13].
Along with these naturally occurring b-lacta-
mases, several acquired b-lactamases have been
identified as a source of carbapenem resistance in
A. baumannii. These enzymes belong either to the
class B enzymes defined by Ambler et al. [14]
(also known as metallo-b-lactamases), or to the
class D enzymes (also known as oxacillinases)
[15]. Although metallo-b-lactamases (MBLs) are
powerful carbapenemases [16], oxacillinases pos-
sessing the ability to hydrolyse imipenem (but not
always meropenem) are grouped in a particular
subgroup of b-lactamases termed carbapenem-
hydrolysing oxacillinases (CHDLs) [17]. Both
MBLs and CHDLs are resistant to inhibition by
clavulanate and tazobactam. MBLs are suscept-
ible in vitro to EDTA inhibition, whereas most
CHDLs are susceptible to NaCl inhibition, thus
providing a means of their laboratory identifica-
tion. Use of Etest strips containing imipenem with
or without EDTA is helpful for identification of
MBL production [16]. Whereas MBLs have been
identified in a wide variety of Gram-negative
species, but only rarely in A. baumannii, most
acquired CHDLs have been identified only in
A. baumannii.
Resistance to carbapenems may also be ex-
plained by other mechanisms, such as porin loss
or modification, as evidenced recently by the
CarO protein (see below), and rarely by modifi-
cation of penicillin-binding proteins (PBPs).
ACQUISITION OF METALLO-
b -LACTAMASE GENES
Five groups of acquired MBLs have been identi-
fied to date (IMP-like, VIM-like, SIM-1, SPM-1
and GIM-1 enzymes), but only the first three of
these groups have been identified in A. baumannii.
The IMP group consists currently of 19 variants
that cluster in seven phylogroups [16]. Six IMP
variants belonging to three different phylogroups
have been identified in A. baumannii, namely IMP-
1 in Italy [18], Japan [19–21] and South Korea [22],
IMP-2 in Italy [23] and Japan [19], IMP-4 in Hong
Kong [24], IMP-5 in Portugal [25], IMP-6 in Brazil
[26], and IMP-11 in Japan [16] (Table 1). In
addition, IMP-4 has been identified in an Acine-
tobacter junii clinical isolate from Australia [27]. Of
note, VIM enzymes have been identified very
rarely in A. baumannii, being represented only by
VIM-2 reported in South Korea [22,28] (Table 1),
which is an area where VIM enzymes are also
known to be widespread in P. aeruginosa and
Enterobacteriaceae. SIM-1 has been reported only
in A. baumannii from South Korea [29], where this
determinant might also be widespread (45th
Interscience Conference on Antimicrobial Agents
and Chemotherapy, abstract C2-107).
The IMP and VIM variants confer a high level
of carbapenem resistance in A. baumannii isolates,
as well as resistance to all b-lactams except
aztreonam, because of their strong hydrolytic
efficiency against these antibiotics. Isolates pro-
ducing SIM-1 have imipenem MICs of 8–16 mg ⁄ L
[29]. The role of MBL production in the carbape-
nem resistance of isolates producing IMP or VIM
enzymes is easy to determine by using the Etest
technique [16]. Using this test, comparison of the
MICs of imipenem alone or combined with EDTA
on an agar plate allows the identification of MBL
production in A. baumannii. Only cefepime and
cefpirome may retain some residual antibacterial
activity against MBL producers, as does, to a
lesser extent, piperacillin-tazobactam.
Table 1. Acquired carbapenem-hydrolysing b-lactamases
identified in Acinetobacter baumannii
b-Lactamase
Ambler
class
Plasmid or
chromosomal Geographical origin
IMP-1 B Plasmid Italy, Japan, South Korea
IMP-2 B Plasmid Italy, Japan
IMP 4 B ? Hong Kong
IMP-5 B ? Portugal
IMP-6 B ? Brazil
IMP-11 B ? Japan
VIM-2 B Plasmid South Korea
SIM-1 B ? South Korea
OXA-23 D Plasmid UK, French Polynesia,
Brazil, Iraq
OXA-24 D Chromosomal Spain
OXA-25 D Chromosomal Spain
OXA-26 D Chromosomal Spain
OXA-27 D ? Singapore
OXA-40 D Chromosomal France, Spain, Portugal
OXA-58 D Plasmid or
Chromosomal
France, Spain, Italy, Greece,
UK, Austria, Romania, Iraq,
Argentina, Kuwait
Poirel and Nordmann Carbapenem resistance in A. baumannii 827
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 826–836
Analysis of the genetic surroundings of the
MBL-encoding genes identified in A. baumannii
has revealed very similar structures, since the
blaIMP, blaVIM or blaSIM genes are embedded in
class-1 integron structures. The MBL genes form
part of the gene cassettes that are inserted
between the 5¢-conserved segment (5¢-CS) and
the 3¢-CS, together with other antibiotic resistance
gene cassettes, mostly encoding aminoglycoside-
modifying enzymes. In addition, the plasmid
location of MBL genes explains their spread
among A. baumannii and P. aeruginosa strains in
specific areas, e.g., Italy and Korea.
ACQUISITION OF CARBAPENEM-
HYDROLYSING OXACILLINASE
GENES
Oxacillinases are unusual b-lactamases that form
a heterogeneous group with respect to their
structural or biochemical properties [15]. These
enzymes usually hydrolyse oxacillin more effi-
ciently than benzylpenicillin. In addition, they
hydrolyse amoxycillin, methicillin, cephaloridine
and, to some extent, cephalothin. Only a few
variants hydrolyse expanded-spectrum cephalo-
sporins (observed in P. aeruginosa, but never in
A. baumannii) and, in such cases, the enzymes
responsible are often point mutant derivatives of
narrow-spectrum enzymes. In contrast, carbapen-
emase activity seems to be an intrinsic property of
some oxacilllinases that are not point-mutant
derivatives of known enzymes. The hydrolytic
efficiency of CHDLs against carbapenems is much
lower (100- to 1000-fold) than that of the MBLs,
which is a property that may complicate their
recognition. CHDLs of this type are identified
frequently in A. baumannii.
Identification of a CHDL-encoding gene was
first reported in A. baumannii in 1995 [30]. This
enzyme, originally named ARI-1, was identified
in Scotland and was found to be plasmid-encoded
[31]. The enzyme was renamed OXA-23 following
its genetic and biochemical characterisation, and
shares 56% amino-acid identity with OXA-51 ⁄ 69
(Fig. 1). OXA-23 is a representative of a CHDL
subgroup that also includes OXA-27 and OXA-49;
OXA-27 was identified in a single carbapenem-
resistant A. baumannii isolate from Singapore
[32], and differs from OXA-23 by Thr to Ala and
Asn to Lys substitutions at positions DBL 95 and
247 [33], respectively, while OXA-49 was identi-
fied in a single A. baumannii isolate from China,
and differs from OXA-23 by a Lys to Glu
substitution at position DBL 178 and an addi-
tional Ala residue at position DBL 222 (GenBank
no. AAP40270). The blaOXA-23 gene has been
identified in two carbapenem-resistant clones that
spread rapidly in hospitals in the UK during 2003
and 2004 [34], and in another clone identified in a
large area of South France (T. Naas, personal
communication). In addition, some OXA-23 pro-
ducers have been identified in Romania [35],
Brazil [36], South Korea [37] and French Polynesia
Fig. 1. Alignment of amino-acid sequences of the four main groups of carbapenem-hydrolysing class D b-lactamases
(CHDLs) identified in Acinetobacter baumannii, including OXA-23, OXA-24 and OXA-58 as representatives of the three
groups of acquired CHDLs, and OXA-51 as a representative of the naturally occurring CHDLs. The conserved residues for
oxacillinases are shaded. Numbering of b-lactamases is according to Ambler class D b-lactamase numbering DBL [33].
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during outbreak periods [38]. Of note, blaOXA-23
has also been identified as being chromosomally
located in a Proteus mirabilis clinical isolate from
France [39].
A second group of CHDLs, comprising OXA-
24, OXA-25, OXA-26 and OXA-40 (sharing 63%
and 60% amino-acid identity with OXA-51 ⁄ 69
and OXA-23, respectively) has also been identi-
fied in A. baumannii (Fig. 1). The OXA-24 and
OXA-25 variants were identified in carbapenem-
resistant A. baumannii isolates recovered from
Spain, whereas OXA-26 was identified in an
isolate from Belgium [32,40]. OXA-40 was identi-
fied in a carbapenem-resistant A. baumannii iso-
late recovered in France from a Portuguese
patient [41] and has also been shown to be
widespread in Spain and Portugal [42–44].
A third group of CHDLs contains OXA-58,
which was identified originally in a carbapenem-
resistant A. baumannii isolate recovered in Tou-
louse, France [45], following an outbreak in a
burns unit [46]. OXA-58 shares 59% amino-acid
identity with OXA-51 ⁄ 69, and < 50% with other
CHDLs (Fig. 1). A series of epidemiological
surveys has identified the blaOXA-58 gene in A.
baumannii clinical isolates from diverse geograph-
ical origins including Spain, Turkey, Romania
[35], Greece [47], Austria, the UK, Argentina,
Kuwait [48] and Italy (A. Carattoli, personal
communication). The blaOXA-58 gene has also been
identified recently in several A. baumannii isolates
recovered from injured USA military personnel in
Iraq (45th Interscience Conference on Infectious
Diseases and Antimicrobial Agents, abstract C2-
1427). Outbreaks involving multiple carbapenem-
resistant clones producing OXA-58 were reported
from the intensive care unit of a hospital in
Athens, Greece [47], and also from several units of
a paediatric hospital in the same city (personal
unpublished data), underlining the fact that OXA-
58-producers constitute an important threat in
Greece. Interestingly, the blaOXA-58 gene has also
been identified in clinical isolates of a different
species, A. junii, from Romania and Australia,
thereby underlining the potential for dissemin-
ation of OXA-23 in the Acinetobacter genus [35].
In addition, it is noteworthy that the A. junii
clinical isolate from Australia co-produced OXA-
58 and IMP-4 b-lactamases, both of which possess
carbapenemase activity [27].
Little is known concerning the acquisition
mechanisms for the CHDL-encoding genes in
A. baumannii. Whereas the blaOXA-23 and blaOXA-58
genes have been identified mostly on plasmids,
the CHDL genes belonging to the blaOXA-24 cluster
seem only to be chromosomally-located. Charac-
terisation of the sequences surrounding blaOXA-40
in several isolates has not provided evidence for
mobilisable elements such as insertion sequences
(IS), transposons or integrons, which is in contrast
to most oxacillinase genes identified in P. aerugi-
nosa, which are integron-borne. It is tempting to
speculate that CHDL genes belonging to the
OXA-23 and OXA-58 clusters are true acquired
resistance genes, whereas genes encoding OXA-
24-like enzymes could belong to a subspecies of
A. baumannii that had acquired this type of gene
in the distant past. The reservoir (natural produ-
cer) of the different CHDLs mentioned above is
unknown, as is the location of the genetic
exchange with A. baumannii. A single CHDL
(OXA-48) [49], found to be plasmid-encoded in a
carbapenem-resistant isolate of Klebsiella pneumo-
niae from Turkey, has been shown to have a
natural reservoir in Shewanella oneidensis [50].
In-silico analyses of GenBank databases and
personal observations have indicated that the
ISAba1 element, belonging to the IS4 family, is
often identified upstream of blaOXA-23, regardless
of the geographical origin of the isolate. In
addition, another IS element, ISAba4, belonging
to the IS982 family, has been identified recently in
A. baumannii clinical isolates from France and
Algeria (personal unpublished data). The pres-
ence of these IS elements upstream of the blaOXA-
23 gene indicates that they may play a role in
blaOXA-23 expression by providing promoter se-
quences, and perhaps they may also have a role in
the acquisition process.
Concerning the blaOXA-58 gene, genetic investi-
gations performed on several non-clonally-related
OXA-58 producers revealed that this gene was
bracketed by IS elements that play a role in its
expression. In particular, ISAba2 (IS3 family),
ISAba3 (IS1 family) and IS18 (IS30 family), as well
as ISAbal, were shown to provide promoter
sequences enhancing blaOXA-58 expression [51].
However, these IS elements were probably not
involved in blaOXA-58 acquisition, and it has been
demonstrated that repeated 27-bp sequences
(named Re27 elements) bracketed a c.5.5-kb frag-
ment containing the blaOXA-58 gene, indicating
that an homologous recombination process may
have been at the origin of such an acquisition [51].
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This would represent the first reported mechan-
ism of acquisition of a b-lactamase gene that was
unrelated to integrons, transposons or IS ele-
ments, but based on recombination events.
Compared with MBLs, the carbapenem resist-
ance level provided by CHDLs in A. baumannii is
much lower. In particular, hydrolysis of merope-
nem is not always detectable with these enzymes.
Since the exact contribution of CHDLs to the
carbapenem resistance of A. baumannii clinical
isolates was debatable, a study was performed to
evaluate this aspect more precisely [52]. The
natural plasmids harbouring the blaOXA-23 and
blaOXA-58 genes were electrotransformed into a
carbapenem-susceptible A. baumannii reference
strain, which then demonstrated a significant
impact of OXA-23 production on resistance by
showing an increased imipenem MIC. However,
this effect was lower when OXA-58 was expressed
in the same A. baumannii reference strain. The
same experiment was repeated using an isogenic
A. baumannii recipient strain that overexpressed its
natural AdeABC efflux system. The resulting
MICs confirmed the important role of OXA-23 in
mediating resistance to carbapenems, but demon-
strated a paradoxically lower contribution of
OXA-58 (16-fold increase in both imipenem and
meropenem MICs) (Fig. 2). Conversely, disruption
of the chromosomal blaOXA-40 gene in a carbape-
nem-resistant isolate of A. baumannii restored
susceptibility to imipenem and meropenem, thus
demonstrating the significant role of OXA-40 in
carbapenem resistance (Fig. 3).
Another interesting feature is the establishment
of a link between production of some of the
naturally occurring OXA-51 ⁄ 69-like oxacillinases
and carbapenem resistance in A. baumannii.
Despite the relatively weak ability of these en-
zymes to hydrolyse carbapenems, it has been
shown that these oxacillinases may sometimes be
overexpressed, resulting in a decreased level of
susceptibility to carbapenems (J. Turton, N. Wood-
ford and T. Pitt, personal communication). This
observation was correlated with the presence of the
ISAba1 element upstream of the blaOXA-51 ⁄ 69-like
gene. Therefore, as observed for the natural
blaAmpC gene ofA. baumannii, ISAba1might provide
promoter sequences that enhance expression of
associated genes. These promoter sequences are
probably extremely efficient inA. baumannii, so that
insertion of ISAba1upstream of blaOXA-51-like genes
might represent a true mechanism of carbapenem
resistance, or at least decreased susceptibility.
Further work is needed to establish precisely the
effect of OXA-51 ⁄ 69 production on resistance to
carbapenems.
PORINS AS A CAUSE OF
CARBAPENEM RESISTANCE
Until recently, knowledge concerning proteins
responsible for the permeability of b-lactam anti-
(A) (B) (C)
Fig. 2. Contribution of the expression of plasmid-mediated OXA-23 and OXA-58 carbapenem-hydrolysing class D
b-lactamase genes in Acinetobacter baumannii [52]. (A) A. baumannii CIP70.10 reference strain; (B) A. baumannii CIP70.10
reference strain possessing a natural plasmid expressing OXA-23; and (C) A. baumannii CIP70.10 reference strain
possessing a natural plasmid expressing OXA-58. TZP, piperacillin-tazobactam; PIP, piperacillin; TIC, ticarcillin; AMX,
amoxycillin; CPO, cefpirome; TCC, ticarcillin-clavulanic acid; CAZ, ceftazidime; CF, cephalothin; FOX, cefoxitin; IPM,
imipenem; AMC, amoxycillin-clavulanic acid; CTX, cefotaxime; CXM, cefuroxime; MOX, moxalactam; ATM, aztreonam;
FEP, cefepime.
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biotics through the outer-membrane of A. bau-
mannii was very limited. By studying the in-vivo
selection of carbapenem resistance in A. baumannii
clinical isolates, Costa et al. [53] demonstrated
that resistant isolates had acquired two b-lacta-
mases, and that these isolates had also lost
a protein of 31–36 kDa.
Recent reports have demonstrated that A.
baumannii possesses outer-membrane proteins
(OMPs) that play a role in carbapenem resistance.
In 2002, Limansky et al. [54] demonstrated that
imipenem resistance was associated with the loss
of a 29-kDa OMP in clinical isolates of A. bauman-
nii in which no carbapenemase activity had been
detected. Similarly, resistance to imipenem and
meropenem in multidrug-resistant A. baumannii
clinical isolates has also been associated with loss
of a heat-modifiable 29-kDa OMP, designated
CarO [55]. When the chromosomal locus contain-
ing the carO gene was cloned from clinical isolates
and characterised, it was shown that only a single
copy of carO, present in a single transcriptional
unit, was present in the A. baumannii genome. The
carO gene encodes a polypeptide of 247 amino-
acid residues, with a typical N-terminal signal
sequence and a predicted trans-membrane b-
barrel topology. The lack of CarO in different
carbapenem-resistant clinical isolates of A. bau-
mannii resulted from the disruption of carO
by distinct insertion elements, supporting the
hypothesis that CarO participates in the influx of
carbapenem antibiotics in A. baumannii. However,
another study that focused on a 25 ⁄ 29-kDa OMP
band of A. baumannii, corresponding to the
so-called CarO, demonstrated that the two bands
corresponded to two proteins that adopted a
typical b-barrel conformation [56]. Only one of
these proteins (the CarO protein) displayed pore-
forming properties, but no binding site for
imipenem was detected in CarO, suggesting a
non-specific monomeric channel function rather
than a specific function, as suggested previously
by Mussi et al. [55].
It has also been reported that resistance to
carbapenems might be associated with reduced
expression of two proteins (22 and 33 kDa) in a
multiresistant A. baumannii isolate that also pro-
duced the CHDL OXA-24 [57], so that both
mechanisms, i.e., carbapenemase production and
decreased permeability, could be responsible
jointly for the high-level carbapenem resistance
observed. Another interesting observation was
made by del Mar Tomas et al. [58], who studied
an A. baumannii isolate that did not produce any
carbapenemase, but exhibited high-level resist-
ance to carbapenems. Analysis of the outer-
membrane profile revealed the loss of a 31- to
36-kDa OMP (later defined as 33- to 36-kDa OMP)
that, on further characterisation, was found to
have an amino-acid sequence and composition
(A) (B)
Fig. 3. Contribution of the expression of the chromosomally-encoded carbapenem-hydrolysing class D b-lactamase OXA-
40 gene in Acinetobacter baumannii [52]. (A) A. baumannii CLA producing OXA-40; and (B) A. baumannii CLA in which the
blaOXA-40 gene has been inactivated by homologous recombination. Abbreviations as for Fig. 2.
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typical of Gram-negative bacterial porins (i.e., a
high glycine content, absence of cysteine residues,
a negative charge, an absence of hydrophobic
residue stretches, and similarity with trans-mem-
brane b barrels, as well as with bacterial mem-
brane and cell-surface proteins) [58]. By using
complementation assays after cloning the corres-
ponding genes on a shuttle plasmid, it was shown
that restored production of the OMP compro-
mised the carbapenem resistance.
A further study has revealed that A. baumannii
possesses an OprD homologue (a porin also
called D2, known to be involved in carbapenem
resistance in P. aeruginosa) [59]. It was demon-
strated that the imipenem susceptibility of A.
baumannii strains producing the OprD-like pro-
tein could be modulated by the addition of basic
amino-acids. Thus, as observed in P. aeruginosa, in
which the OprD porin has a major role in
imipenem resistance and is also involved in basic
amino-acid uptake, carbapenem-susceptible A.
baumannii isolates express naturally an OprD-like
protein of 43 kDa.
OTHER NON-ENZYMIC
MECHANISMS AND CARBAPENEM
RESISTANCE
Modification of penicillin-binding-proteins (PBPs)
as a source of imipenem resistance in A. baumannii
has been investigated only rarely. Gehrlein et al.
[60] studied a carbapenem-susceptible isolate and
a derived resistant mutant obtained in vitro, and
showed that the resistant mutant hyper-produced
a 24-kDa PBP, but produced six other PBPs at a
lower level. Another study has described the
existence of 12 PBP patterns among a collection of
A. baumannii isolates with variable b-lactam
resistance profiles [61]. In isolates with imipenem
MICs > 4 mg ⁄ L, the absence of a 73.2-kDa PBP
was associated with resistance in conjunction
with production of carbapenemases.
An AdeABC efflux system has been identified
in A. baumannii [62]. This efflux mechanism
belongs to the resistance-nodulation-division
(RND) family of efflux systems [63], known to
accommodate a broad range of structurally unre-
lated molecules, including most classes of antibi-
otics. Its role in resistance to aminoglycosides and
in decreased susceptibility to chloramphenicol,
fluoroquinolones and trimethoprim, as well as
cefotaxime, has been demonstrated clearly [62].
However, its effect on carbapenem susceptibility
was not initially evaluated. Further studies iden-
tified the adeST genes, encoding homologues of
the sensor kinase ⁄ response regulator members of
the superfamily of bacterial two-component reg-
ulators, upstream of the adeABC efflux genes [64].
The corresponding proteins were shown to be
implicated in regulating efflux gene expression.
By analysing the carbapenem susceptibility levels
of strain CIP70.10 and its point mutant derivative
BM4547 (in which this regulatory system was
inactivated), a two-fold increase in the MICs of
imipenem and meropenem was demonstrated
when the AdeABC system was expressed consti-
tutively [52]. In addition, when combined with
production of a CHDL, a synergic effect was
observed that resulted (e.g.) in a carbapenem
resistance level with OXA-58 that was not reached
with the same enzyme in the wild-type strain
background [52]. Consequently, it appears that
the AdeABC efflux system may also contribute to
carbapenem resistance in A. baumannii.
CLINICAL FEATURES OF
CARBAPENEM-RESISTANT
ISOLATES
Spread of a single A. baumannii isolate as a source
of a nosocomial outbreak is often linked to con-
tamination of respiratory equipment and trans-
mission via the hands of hospital staff [1,65].
Numerous studies have shown that the hospital
environment is a preferential setting in which A.
baumannii isolates can persist and develop. A. bau-
mannii seems to have unique characteristics among
nosocomial Gram-negative bacteria that enhance
its environmental persistence. The possibility that
the community represents a reservoir for A. bau-
mannii was evaluated by analysing and comparing
isolates recovered from patients in two hospitals in
New York, USA, with isolates recovered from the
hands of individuals in the community [66]. This
study showed clearly that community isolates are
distinct from those encountered in hospital set-
tings, whereas hospitals constitute reservoirs for
clonal diffusion. In addition, an absence of multi-
drug resistance was demonstrated in the commu-
nity isolates, thereby confirming that the battle
against increased carbapenem resistance should
take place primarily in the hospital.
Another interesting aspect of the relationship
between carbapenem resistance and CHDL
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production was demonstrated by the recent find-
ing of a carbapenem-susceptible isolate that was
related clonally to a carbapenem-resistant isolate
in a hospital environment. Genetic investigations
revealed loss of the CHDL-encoding gene in the
susceptible isolate in the absence of antibiotic
selection pressure [51]. Even if such observations
cannot be extended to all of the carbapenem
resistance mechanisms described in this review,
the possibility that such resistance mechanisms
might be reversible clearly strengthens the theory
that control of antibiotic consumption may play a
significant role in preventing resistance. In addi-
tion, it has been shown that some hospitals may
face concomitant outbreaks of multidrug-resistant
and multidrug-susceptible subclones of A. bau-
mannii [67].
Cisneros et al. [68] analysed potential risk-
factors for the acquisition of imipenem-resistant
A. baumannii recovered from a series of Spanish
hospitals. Among a cohort of 203 patients, 43%
were resistant to imipenem, and a wide and
multiple clonal distribution was demonstrated,
although local spread of particular clones leading
to outbreaks was not demonstrated. The major
risk-factors identified were a hospital size of > 500
beds, previous antimicrobial treatment, use of a
urinary catheter, and surgery. This analysis led to
the suggestion that a key element in control
should be better differentiation between coloni-
sation and infection in order to limit inappro-
priate use of antimicrobial agents. Evaluation of
risk-factors for colonisation and infection by a
carbapenem-resistant isolate in a hospital out-
break context has revealed an independent associ-
ation with the presence of arterial catheters and
the use of imipenem as monotherapy [69], and
also an association with pulsative lavage wound
treatment [70]. It has been shown that multidrug-
resistant A. baumannii, defined by carbapenem
resistance alone [4], may result from successive
contaminations with different strains in a given
hospital unit, rather than an increase in resistance
by successive steps in a single clone, which makes
control more difficult [65].
CONCLUSIONS
The recent identification of the largest antibiotic
resistance island known so far (more than 40
resistance genes) [71] in a carbapenem-susceptible
and ESBL-producing A. baumannii clinical isolate
[72] demonstrates the genetic plasticity of A.
baumannii which enables it to benefit from a
variety of resistance mechanisms to easily become
more and more resistant when antibiotic pressure
is maintained. By chance, although A. baumannii
is known to have the propensity to develop
antibiotic resistance rapidly [1], it seems that
in-vitro selection of carbapenem resistance in A.
baumannii is difficult to achieve. However, the
presence of carbapenem-resistant isolates in
hospital wards results mostly from the acquisition
of carbapenem-hydrolysing b-lactamases. Thus,
production of a CHDL seems to constitute the
main problem. In the USA, the proportion of
Acinetobacter isolates resistant or intermediately-
resistant to imipenem rose from 6.3% in 1999 to
11.4% in 2001 [73]. The recent evidence of A.
baumannii infections among patients at military
facilities treating injured USA service personnel
has reinforced the need for better control [74]. In
terms of therapy, some studies have indicated
that colistin may be useful for treating infections
caused by carbapenem-resistant strains. The
debate surrounding the efficacy of this antibiotic
remains open, but the resolution of bacteraemia
caused by strains of multidrug-resistant A. bau-
mannii with a continuous intravenous infusion of
colistin has been demonstrated [74,75]. In addi-
tion, in-vivo experimental studies have indicated
that use of carbapenems could still be appropriate
in certain circumstances. For example, in a mouse
model of pneumonia, Montero et al. [76] demon-
strated that the best therapeutic approach
involved a combination of imipenem and amino-
glycosides in the case of moderate levels of
carbapenem resistance, and a combination of
imipenem and colistin or tobramycin or rifampi-
cin in the case of high-level imipenem resistance.
Combinations of polymyxin B, imipenem and
rifampicin have been shown to be synergic in vitro
[77,78], although there is some debate regarding
the fractional inhibitory concentration index
score. Tigecycline might also be useful, since
tigecycline is known to be effective against some
carbapenemase-producing strains and might be a
useful alternative to polymyxins [79]. A combi-
nation of ampicillin and sulbactam has been
shown to be effective against multiresistant iso-
lates for the treatment of life-threatening acine-
tobacter infections [80]. Nevertheless, as the main
problem identified in epidemiological surveys
appears to be related to the production of CHDLs,
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it is clear that there is a specific need for a potent
class D b-lactamase inhibitor to prevent, at least
partially, current therapeutic failures.
REFERENCES
1. Bergogne-Be´re´zin E, Towner KJ. Acinetobacter spp. as no-
socomial pathogens: microbiological, clinical, and epide-
miological features. Clin Microbiol Rev 1996; 9: 148–165.
2. Coelho J, Woodford N, Turton J, Livermore DM. Multi-
resistant acinetobacter in the UK: how big a threat? J Hosp
Infect 2004; 58: 167–169.
3. Richet HM, Mohammed J, McDonald LC, Jarvis WR.
INSPEAR. Building communication networks: interna-
tional network for the study and prevention of emerging
antimicrobial resistance. Emerg Infect Dis 2001; 7: 319–
322.
4. Kluytmans-Vandenbergh MFQ, Kluytmans JAJW, Voss A.
Dutch guideline for preventing nosocomial transmission
of highly resistant microorganisms (HRMO). Infection
2005; 5/6: 309–313.
5. Bou G, Martinez-Beltran J. Cloning, nucleotide sequen-
cing, and analysis of the gene encoding an AmpC b-lac-
tamase in Acinetobacter baumannii. Antimicrob Agents
Chemother 2000; 44: 428–432.
6. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H,
Reynaud A. AmpC cephalosporinase hyperproduction in
Acinetobacter baumannii clinical strains. J Antimicrob Chem-
other 2003; 52: 629–635.
7. He´ritier C, Poirel L, Nordmann P. Cephalosporinase over-
expression resulting from insertion of ISAba1 in Acineto-
bacter baumannii. Clin Microbiol Infect 2006; 12: 123–130.
8. Segal H, Nelson EC, Elisha BG. Genetic environment of
ampC in Acinetobacter baumannii clinical isolate. Antimicrob
Agents Chemother 2004; 48: 612–614.
9. He´ritier C, Poirel L, Fournier PE, Claverie JM, Raoult D,
Nordmann P. Characterization of the naturally occurring
oxacillinase of Acinetobacter baumannii. Antimicrob Agents
Chemother 2005; 49: 4174–4179.
10. Brown S, Young HK, Amyes SG. Characterisation of
OXA-51, a novel class D carbapenemase found in
genetically unrelated clinical strains of Acinetobacter
baumannii from Argentina. Clin Microbiol Infect 2005; 11:
15–23.
11. Brown S, Amyes SG. The sequences of seven class D
b-lactamases isolated from carbapenem-resistant
Acinetobacter baumannii from four continents. Clin Microbiol
Infect 2005; 11: 326–329.
12. Brown S, Amyes SG. OXA b-lactamases in Acinetobacter:
the story so far. J Antimicrob Chemother 2006; 57: 1–3.
13. Girlich D, Naas T, Nordmann P. Biochemical characteri-
zation of the naturally occurring oxacillinase OXA-50 of
Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004;
48: 2043–2048.
14. Ambler RP, Coulson AF, Fre`re JM et al. A standard num-
bering scheme for the class A b-lactamases. Biochem J 1991;
276: 269–227.
15. Naas T, Nordmann P. OXA-type b-lactamases. Curr Pharm
Des 1999; 5: 865–879.
16. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-b-
lactamases: the quiet before the storm? Clin Microbiol Rev
2005; 18: 306–325.
17. Nordmann P, Poirel L. Emerging carbapenemases in
Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321–
331.
18. Cornaglia G, Riccio ML, Mazzariol A et al. Appearance of
IMP-1 metallo-b-lactamase in Europe. Lancet 1999; 353:
899–900.
19. Shibata N, Doi Y, Yamane K et al. PCR typing of genetic
determinants for metallo-b-lactamases and integrases
carried by gram-negative bacteria isolated in Japan, with
focus on the class 3 integron. J Clin Microbiol 2003; 41:
5407–5413.
20. Nishio H, Komatsu M, Shibata N et al. Metallo-b-lacta-
mase-producing gram-negative bacilli: laboratory-based
surveillance in cooperation with 13 clinical laboratories in
the Kinki region of Japan. J Clin Microbiol 2004; 42: 5256–
5263.
21. Takahashi A, Yomoda S, Kobayashi I, Okubo T, Tsunoda
M, Iyobe S. Detection of carbapenemase-producing Aci-
netobacter baumannii in a hospital. Antimicrob Agents
Chemother 2000; 38: 526–529.
22. Lee K, Lee WG, Uh Y et al. VIM- and IMP-type metallo-b-
lactamase-producing Pseudomonas spp. and Acinetobacter
spp. in Korean hospitals. Emerg Infect Dis 2003; 9: 868–871.
23. Riccio ML, Franceschini N, Boschi L et al. Characterization
of the metallo-b-lactamase determinant of Acinetobacter
baumannii AC-54 ⁄ 97 reveals the existence of blaIMP allelic
variants carried by gene cassettes of different phylogeny.
Antimicrob Agents Chemother 2000; 44: 1229–1235.
24. Chu YW, Afzal-Shah M, Houang ET et al. IMP-4, a novel
metallo-b-lactamase from nosocomial Acinetobacter spp.
collected in Hong Kong between 1994 and 1998. Antimicrob
Agents Chemother 2001; 45: 710–714.
25. Da Silva GJ, Correia M, Vital C et al. Molecular charac-
terization of blaIMP-5, a new integron-borne metallo-b-lac-
tamase gene from an Acinetobacter baumannii nosocomial
isolate in Portugal. FEMS Microbiol Lett 2002; 215: 33–39.
26. Gales AC, Tognim MC, Reis AO et al. Emergence of an
IMP-like metallo-enzyme in an Acinetobacter baumannii
clinical strain from a Brazilian teaching hospital. Diagn
Microbiol Infect Dis 2003; 45: 77–79.
27. Peleg AY, Franklin C, Walters LJ, Bell JM, Spelman DW.
OXA-58 and IMP-4 carbapenem-hydrolyzing b-lactamases
in an Acinetobacter junii blood culture from Australia.
Antimicrob Agents Chemother 2006; 50: 399–400.
28. Yum JH, Yi K, Lee H et al. Molecular characterization of
metallo-b-lactamase-producing Acinetobacter baumannii
and Acinetobacter genomospecies 3 from Korea: identifi-
cation of two new integrons carrying the blaVIM-2 gene
cassettes. J Antimicrob Chemother 2002; 49: 837–840.
29. Lee K, Yum JH, Yong D et al. Novel acquired metallo-b-
lactamase gene, bla (SIM-1), in a class 1 integron from
Acinetobacter baumannii clinical isolates from Korea. Anti-
microb Agents Chemother 2005; 49: 4485–4491.
30. Scaife W, Young HK, Paton RH, Amyes SG. Transferable
imipenem-resistance in Acinetobacter species from a clinical
source. J Antimicrob Chemother 1995; 36: 585–586.
31. Donald HM, Scaife W, Amyes SG, Young HK. Sequence
analysis of ARI-1, a novel OXA b-lactamase, responsible
for imipenem resistance in Acinetobacter baumannii 6B92.
Antimicrob Agents Chemother 2000; 44: 196–199.
32. Afzal-Shah M, Woodford N, Livermore D. Characteriza-
tion of OXA-25, OXA-26, and OXA-27, molecular class D
b-lactamases associated with carbapenem resistance in
834 Clinical Microbiology and Infection, Volume 12 Number 9, September 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 826–836
clinical isolates of Acinetobacter baumannii. Antimicrob
Agents Chemother 2001; 45: 583–588.
33. Couture F, Lachapelle J, Le´vesque RC. Phylogeny of LCR-
1 and OXA-5 with class A and class D b-lactamases. Mol
Microbiol 1992; 6: 1693–1705.
34. Turton JF, Kaufmann ME, Glover J et al. Detection and
typing of integrons in epidemic strains of Acinetobacter
baumannii found in the United Kingdom. J Clin Microbiol
2005; 43: 3074–3082.
35. Marque´ S, Poirel L, He´ritier C et al. Regional occurrence of
plasmid-mediated carbapenem-hydrolyzing oxacillinase
OXA-58 in Acinetobacter spp. in Europe. J Clin Microbiol
2005; 43: 4885–4888.
36. Dalla-Costa LM, Coelho JM, Souza HA et al. Outbreak of
carbapenem-resistant Acinetobacter baumannii producing
the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol
2003; 41: 3403–3406.
37. Jeon BC, Jeong SH, Bae IK et al. Investigation of a
nosocomial outbreak of imipenem-resistant Acinetobacter
baumannii producing the OXA-23 b-lactamase in Korea.
J Clin Microbiol 2005; 43: 2241–2245.
38. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann
P. Outbreak of carbapenem-resistant Acinetobacter bau-
mannii producing the carbapenemase OXA-23 in a tertiary
care hospital of Papeete, French Polynesia. J Clin Microbiol
2005; 43: 4826–4829.
39. Bonnet R, Marchandin H, Chanal C et al. Chromosome-
encoded class D b-lactamase OXA-23 in Proteus mirabilis.
Antimicrob Agents Chemother 2002; 46: 2004–2006.
40. Bou G, Oliver A, Martinez-Beltran A. OXA-24, a novel
class D b-lactamase with carbapenemase activity in an
Acinetobacter baumannii clinical strain. Antimicrob Agents
Chemother 2000; 44: 1556–1561.
41. He´ritier C, Poirel L, Aubert D, Nordmann P. Genetic and
functional analysis of the chromosome-encoded carbape-
nem-hydrolyzing oxacillinase OXA-40 of Acinetobacter
baumannii. Antimicrob Agents Chemother 2003; 47: 268–273.
42. Lopez-Otsoa F, Gallego L, Towner KJ, Tysall L, Woodford
N, Livermore DM. Endemic carbapenem resistance asso-
ciated with OXA-40 carbapenemase among Acinetobacter
baumannii isolates from a hospital in northern Spain. J Clin
Microbiol 2002; 40: 4741–4743.
43. Peixe L. Emergence of carbapenem-hydrolyzing enzymes
in Acinetobacter baumannii clinical isolates. J Clin Microbiol
1999; 37: 2109–2110.
44. Da Silva GJ, Quinteira S, Bertolo E et al. Long-term
dissemination of an OXA-40 carbapenemase-producing
Acinetobacter baumannii clone in the Iberian Peninsula.
J Antimicrob Chemother 2004; 54: 255–258.
45. Poirel L, Marque´ S, He´ritier C, Segonds C, Chabanon G,
Nordmann P. OXA-58, a novel class D b-lactamase in-
volved in resistance to carbapenems in Acinetobacter bau-
mannii. Antimicrob Agents Chemother 2005; 49: 202–208.
46. He´ritier C, Dubouix A, Poirel L, Marty N, Nordmann P. A
nosocomial outbreak of Acinetobacter baumannii isolates
expressing the carbapenem-hydrolysing oxacillinase OXA-
58. J Antimicrob Chemother 2005; 55: 115–118.
47. Pournaras S, Markogiannakis A, Ikonomidis A et al. Out-
break of multiple clones of imipenem-resistantAcinetobacter
baumannii isolates expressing OXA-58 carbapenemase in an
intensive care unit. J Antimicrob Chemother 2006; 57: 557–561.
48. Coelho J, Woodford N, Afzal-Shah M, Livermore D.
Occurrence of OXA-58-like carbapenemases in Acineto-
bacter spp. collected over 10 years in three continents.
Antimicrob Agents Chemother 2006; 50: 756–758.
49. Poirel L, He´ritier C, Tolu¨n V, Nordmann P. Emergence of
oxacillinase-mediated resistance to imipenem in Klebsiella
pneumoniae. Antimicrob Agents Chemother 2004; 48: 15–22.
50. Poirel L, He´ritier C, Nordmann P. Chromosome-encoded
Ambler class D b-lactamase of Shewanella oneidensis as a
progenitor of carbapenem-hydrolyzing oxacillinase. Anti-
microb Agents Chemother 2004; 48: 348–351.
51. Poirel L, Nordmann P. Genetic structures at the origin of
acquisition and expression of the carbapenem-hydrolyzing
oxacillinase gene blaOXA-58 in Acinetobacter baumannii.
Antimicrob Agents Chemother 2006; 50: 1442–1448.
52. He´ritier C, Poirel L, Lambert T, Nordmann P. Contribution
of acquired carbapenem-hydrolyzing oxacillinases to
carbapenem resistance in Acinetobacter baumannii. Anti-
microb Agents Chemother 2005; 49: 3198–3202.
53. Costa SF, Woodcock J, Gill M et al. Outer-membrane pro-
teins pattern and detection of b-lactamases in clinical iso-
lates of imipenem-resistant Acinetobacter baumannii from
Brazil. Int J Antimicrob Agents 2000; 13: 175–182.
54. Limansky AS, Mussi MA, Viale AM. Loss of a 29-kilo-
dalton outer membrane protein in Acinetobacter baumannii
is associated with imipenem resistance. J Clin Microbiol
2002; 40: 4776–4778.
55. Mussi MA, Limansky AS, Viale AM. Acquisition of
resistance to carbapenems in multidrug-resistant clinical
strains of Acinetobacter baumannii: natural insertional
inactivation of a gene encoding a member of a novel
family of b-barrel outer membrane proteins. Antimicrob
Agents Chemother 2005; 49: 1432–1440.
56. Siroy A, Molle V, Lemaitre-Guillier C et al. Channel for-
mation by CarO, the carbapenem resistance-associated
outer membrane protein of Acinetobacter baumannii. Anti-
microb Agents Chemother 2005; 49: 4876–4883.
57. Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-
Beltran J. Characterization of a nosocomial outbreak caused
by a multiresistant Acinetobacter baumannii strain with a
carbapenem-hydrolyzing enzyme: high-level carbapenem
resistance inA. baumannii is not due solely to the presence of
b-lactamases. J Clin Microbiol 2000; 38: 3299–3305.
58. del Mar Tomas M, Beceiro A, Perez A et al. Cloning and
functional analysis of the gene encoding the 33- to
36-kilodalton outer membrane protein associated with
carbapenem resistance in Acinetobacter baumannii. Anti-
microb Agents Chemother 2005; 49: 5172–5175.
59. Dupont M, Pages JM, Lafitte D, Siroy A, Bollet C. Identi-
fication of an OprD homologue in Acinetobacter baumannii.
J Proteome Res 2005; 4: 2386–2390.
60. Gehrlein M, Leying H, Cullman W, Wendt S, Opferkuch
W. Imipenem resistance in Acinetobacter baumannii is due
to altered penicillin-binding proteins. Chemotherapy 1991;
37: 405–412.
61. Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC,
Ayala JA, Perea EJ, Pascual A. Relationship between
b-lactamase production, outer membrane protein and
penicillin-binding protein profiles on the activity of carb-
apenems against clinical isolates of Acinetobacter bauman-
nii. J Antimicrob Chemother 2003; 51: 565–574.
62. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-
cell division-type efflux pump involved in aminoglycoside
resistance in Acinetobacter baumannii strain BM4454. Anti-
microb Agents Chemother 2001; 45: 3375–3380.
Poirel and Nordmann Carbapenem resistance in A. baumannii 835
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 826–836
63. Poole K. Efflux-mediated multiresistance in Gram-negat-
ive bacteria. Clin Microbiol Infect 2004; 10: 12–26.
64. Marchand I, Damier-Piolle L, Courvalin P, Lambert T.
Expression of the RND-type efflux pump AdeABC in
Acinetobacter baumannii is regulated by the AdeRS two-
component system. Antimicrob Agents Chemother 2004; 48:
3298–3304.
65. Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia
due to Acinetobacter baumannii: epidemiology, clinical fea-
tures and treatment. Clin Microbiol Infect 2002; 8: 687–693.
66. Zeana C, Larson E, Sahni J, Baguya SJ, Wu F, Della-Latta P.
The epidemiology of multidrug-resistant Acinetobacter
baumannii: does the community represent a reservoir?
Infect Control Hosp Epidemiol 2003; 24: 275–279.
67. Maslow JN, Glaze T, Adams P, Lataillade M. Concurrent
outbreak of multidrug-resistant and susceptible subclones
of Acinetobacter baumannii affecting different wards of a
single hospital. Infect Control Hosp Epidemiol 2005; 26: 69–
75.
68. Cisneros JM, Rodriguez-Bano J, Fernandez-Cuenca F et al.
Risk-factors for the acquisition of imipenem-resistant Aci-
netobacter baumannii in Spain: a nationwide study. Clin
Microbiol Infect 2005; 11: 874–879.
69. del Mar Tomas M, Cartelle M, Pertega S et al. Hospital
outbreak caused by a carbapenem-resistant strain of Aci-
netobacter baumannii: patient prognosis and risk-factors for
colonisation and infection. Clin Microbiol Infect 2005; 11:
540–546.
70. Maragakis LL, Cosgrove SE, Song X et al. An outbreak of
multidrug-resistant Acinetobacter baumannii associated
with pulsatile lavage wound treatment. JAMA 2004; 292:
3006–3011.
71. Fournier PE, Vallenet D, Barbe V et al. Comparative ge-
nomics of multidrug resistance in Acinetobacter baumannii.
PLoS Genet 2006; 2: e7.
72. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P.
Outbreak of extended-spectrum b-lactamase VEB-1-pro-
ducing isolates of Acinetobacter baumannii in a French
hospital. J Clin Microbiol 2003; 41: 3542–3547.
73. Livermore DM. Threat from the pink corner. Ann Med
2003; 35: 226–234.
74. Centers for Disease Control and Prevention (CDC). Aci-
netobacter baumannii infections among patients at military
medical facilities treating injured U.S. service members,
2002–04. MMWR Morb Mortal Wkly Rep 2004; 53: 1063–
1066.
75. Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas
ME. Cure of multidrug-resistant Acinetobacter baumannii
bacteraemia with continuous intravenous infusion of
colistin. Scand J Infect Dis 2005; 37: 142–145.
76. Montero A, Ariza J, Corbella X et al. Antibiotic combina-
tions for serious infections caused by carbapenem-resist-
ant Acinetobacter baumannii in a mouse pneumonia model.
J Antimicrob Chemother 2004; 54: 1085–1091.
77. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. In vitro
double and triple synergistic activities of polymyxin B,
imipenem, and rifampin against multidrug-resistant Aci-
netobacter baumannii. Antimicrob Agents Chemother 2004; 48:
753–757.
78. Wareham DW, Bean DC, Urban CM, Rahal JJ. In vitro
activities of polymyxin B, imipenem, and rifampin against
multidrug-resistant Acinetobacter baumannii. Antimicrob
Agents Chemother 2006; 50: 825–826.
79. Livermore DM. Tigecycline: what is it, and where should it
be used? J Antimicrob Chemother 2005; 56: 611–614.
80. Levin AS. Multiresistant Acinetobacter infections: a role for
sulbactam combinations in overcoming an emerging
worldwide problem. Clin Microbiol Infect 2002; 8: 144–153.
836 Clinical Microbiology and Infection, Volume 12 Number 9, September 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 826–836
